Observational evidence of third dredge-up occurrence in S-type stars with initial masses around 1 Msun

Context- S stars are late-type giants with spectra showing characteristic molecular bands of ZrO in addition to the TiO bands typical of M stars. Their overabundance pattern shows the signature of s-process nucleosynthesis. Intrinsic, technetium (Tc)-rich S stars are the first objects, on the Asymptotic Giant Branch (AGB), to undergo third dredge-up (TDU) events. Gaia exquisite parallaxes now allow to precisely locate these stars in the Hertzsprung-Russell (HR) diagram. Here we report on a population of low-mass, Tc-rich S stars, previously unaccounted for by stellar evolution models. Aims- Our aim is to derive parameters of a sample of low-mass Tc-rich S stars and then, by comparing their location in the HR diagram with stellar evolution tracks, to derive their masses and to compare their measured s-process abundance profiles with recently derived STAREVOL nucleosynthetic predictions for low-mass AGB stars. Methods- The stellar parameters were obtained using a combination of HERMES high-resolution spectra, accurate Gaia Data Release 2 (Gaia-DR2) parallaxes, stellar-evolution models and newly-designed MARCS model atmospheres for S-type stars. Results- We report on 6 Tc-rich S stars lying close to the 1 Msun (initial mass) tracks of AGB stars of the corresponding metallicity and above the predicted onset of TDU, as expected. This provides direct evidence for TDUs occurring in AGB stars with initial masses as low as ~ 1 Msun and at low luminosity, i.e. at the start of the thermally-pulsing AGB. We present AGB models producing TDU in those stars with [Fe/H] in the range -0.25 to -0.5. There is a reasonable agreement between the measured and predicted s-process abundance profiles. For 2 objects however (CD -29 5912 and BD +34 1698), the predicted C/O ratio and s-process enhancements do not match simultaneously the measured ones.Comment: Recommended for publication in A&A letter

Abundance Patterns in S-type AGB stars : Setting Constraints on Nucleosynthesis and Stellar Evolution Models

During the evolution on the AGB, S-type stars are the first objects to experience s-process nucleosynthesis and third dredge-ups, and therefore to exhibit sprocess signatures in their atmospheres. Their significant mass loss rates (10^-7 to 10^-6 M*/year) make them major contributors to the AGB nucleosynthesis yields at solar metallicity. Precise abundance determinations in S stars are of the utmost importance for constraining e.g. the third dredge-up luminosity and efficiency (which has been only crudely parameterized in all current nucleosynthetic models so far). Here, dedicated S-star model atmospheres are used to determine precise abundances of key s-process elements, and to set constraints on nucleosynthesis and stellar evolution models. A special interest is paid to technetium, an element with no stable isotopes (99Tc, the only isotope produced by the s-process in AGB stars, has a half-life of 2.1 x 10^5 years). Its detection is considered as the best signature that the star effectively populates the thermally-pulsing AGB phase of evolution. The derived Tc/Zr abundances are compared, as a function of the derived [Zr/Fe] overabundances, with AGB stellar model predictions. The [Zr/Fe] overabundances are in good agreement with the model predictions, while the Tc/Zr abundances are slightly overpredicted. This discrepancy can help to set better constraints on nucleosynthesis and stellar evolution models of AGB stars.Comment: 5 pages, 3 figures, To be published in the proceedings of the conference "Why Galaxies Care about AGB Stars II", held in Vienna, August 16-20, 2010; eds Franz Kerschbaum, Thomas Lebzelter, and Bob Wing, ASP Conf. Serie

Titans metal-poor reference stars II. Red giants and CEMP stars

Representative samples of F-, G-, K-type stars located out of the Solar Neighbourhood has started to be available in spectroscopic surveys. The fraction of metal-poor ([Fe/H]~$\lesssim -0.8$~dex) giants becomes increasingly relevant to far distances. In metal-poor stars, effective temperatures ($T_{\mathrm{eff}}$) based on LTE spectroscopy and on former colour-$T_{\mathrm{eff}}$ relations of still wide use have been reported to be inaccurate. It is necessary to re-calibrate chemical abundances based on these $T_{\mathrm{eff}}$ scales in the multiple available surveys to bring them to the same standard scale for their simultaneous use. For that, a complete sample of standards is required, which so far, is restricted to a few stars with quasi-direct $T_{\mathrm{eff}}$ measurements. We aim at providing a legacy sample of metal-poor standards with proven accurate atmospheric parameters. We add 47 giants to the sample of metal-poor dwarfs of Giribaldi et al. 2021, thereby constituting the Titans metal-poor reference stars. $T_{\mathrm{eff}}$ was derived by 3D non-LTE H$\alpha$ modelling, whose accuracy was tested against interferometry and InfraRed Flux Method (IRFM). Surface gravity (log $g$) was derived by fitting Mg~I~b triplet lines, whose accuracy was tested against asteroseismology. Metallicity was derived using Fe II lines, which was verified to be identical to the [Fe/H] derived from non-LTE spectral synthesis. $T_{\mathrm{eff}}$ from 3D non-LTE H$\alpha$ is equivalent to interferometric and IRFM temperatures within a $\pm$46~K uncertainty. We achieved precision of $\sim$50~K for 34 stars with spectra with the highest S/N. For log $g$, we achieved a total uncertainty of $\pm$0.15~dex. For [Fe/H], we obtained a total uncertainty of $\pm$0.09~dex. We find that the ionization equilibrium of Fe lines under LTE is not valid in metal-poor giants.Comment: Accepted in A&

Re-producing public space: the changing everyday production of outdoor retail markets

In 2020, nation states across Europe restricted access to, and use of, public space to prevent the spread of COVID-19. As almost all public spaces in Europe were consequently affected by restrictive measures, so too did outdoor retail markets drastically change. Some had to close down completely, whereas others operated under the sway of severe limitations for traders and customers. By re-engaging with the work of the late Michael Sorkin, it could be argued that the effects of COVID-19 add another dimension to the “end” or “death” of public space. In this paper, we shift attention to the tactics and strategies of one category of public figures behind the everyday production of markets, the traders, to show that markets in Spain, the United Kingdom, Switzerland and the Netherlands did not simply stop functioning as public spaces. Rather, they took on different forms that extended spatially beyond their physical boundaries. These transformations allowed for the continuation of the social and political dimensions of public space

Women Scientists Who Made Nuclear Astrophysics

Female role models reduce the impact on women of stereotype threat, i.e., of being at risk of conforming to a negative stereotype about one's social, gender, or racial group [1,2]. This can lead women scientists to underperform or to leave their scientific career because of negative stereotypes such as, not being as talented or as interested in science as men. Sadly, history rarely provides role models for women scientists; instead, it often renders these women invisible [3]. In response to this situation, we present a selection of twelve outstanding women who helped to develop nuclear astrophysics

Stellar Astrophysics and Exoplanet Science with the Maunakea Spectroscopic Explorer (MSE)

The Maunakea Spectroscopic Explorer (MSE) is a planned 11.25-m aperture facility with a 1.5 square degree field of view that will be fully dedicated to multi-object spectroscopy. A rebirth of the 3.6m Canada-France-Hawaii Telescope on Maunakea, MSE will use 4332 fibers operating at three different resolving powers (R ~ 2500, 6000, 40000) across a wavelength range of 0.36-1.8mum, with dynamical fiber positioning that allows fibers to match the exposure times of individual objects. MSE will enable spectroscopic surveys with unprecedented scale and sensitivity by collecting millions of spectra per year down to limiting magnitudes of g ~ 20-24 mag, with a nominal velocity precision of ~100 m/s in high-resolution mode. This white paper describes science cases for stellar astrophysics and exoplanet science using MSE, including the discovery and atmospheric characterization of exoplanets and substellar objects, stellar physics with star clusters, asteroseismology of solar-like oscillators and opacity-driven pulsators, studies of stellar rotation, activity, and multiplicity, as well as the chemical characterization of AGB and extremely metal-poor stars.Comment: 31 pages, 11 figures; To appear as a chapter for the Detailed Science Case of the Maunakea Spectroscopic Explore

Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.

Abstract Background Though the Expanded Disability Status Scale (EDSS) is commonly used to assess disability level in relapsing-remitting multiple sclerosis (RRMS), the criteria defining disability progression are used for patients with a wide range of baseline levels of disability in relatively short-term trials. As a result, not all EDSS changes carry the same weight in terms of future disability, and treatment benefits such as decreased risk of reaching particular disability milestones may not be reliably captured. The objectives of this analysis are to assess the probability of confirmed disability worsening to specific EDSS milestones (i.e., EDSS scores ≥3.0, ≥4.0, or ≥6.0) at 288 weeks in the Tysabri Observational Program (TOP) and to examine the impact of relapses occurring during natalizumab therapy in TOP patients who had received natalizumab for ≥24 months. Methods TOP is an ongoing, open-label, observational, prospective study of patients with RRMS in clinical practice. Enrolled patients were naive to natalizumab at treatment initiation or had received ≤3 doses at the time of enrollment. Intravenous natalizumab (300 mg) infusions were given every 4 weeks, and the EDSS was assessed at baseline and every 24 weeks during treatment. Results Of the 4161 patients enrolled in TOP with follow-up of at least 24 months, 3253 patients with available baseline EDSS scores had continued natalizumab treatment and 908 had discontinued (5.4% due to a reported lack of efficacy and 16.4% for other reasons) at the 24-month time point. Those who discontinued due to lack of efficacy had higher baseline EDSS scores (median 4.5 vs. 3.5), higher on-treatment relapse rates (0.82 vs. 0.23), and higher cumulative probabilities of EDSS worsening (16% vs. 9%) at 24 months than those completing therapy. Among 24-month completers, after approximately 5.5 years of natalizumab treatment, the cumulative probabilities of confirmed EDSS worsening by 1.0 and 2.0 points were 18.5% and 7.9%, respectively (24-week confirmation), and 13.5% and 5.3%, respectively (48-week confirmation). The risks of 24- and 48-week confirmed EDSS worsening were significantly higher in patients with on-treatment relapses than in those without relapses. An analysis of time to specific EDSS milestones showed that the probabilities of 48-week confirmed transition from EDSS scores of 0.0–2.0 to ≥3.0, 2.0–3.0 to ≥4.0, and 4.0–5.0 to ≥6.0 at week 288 in TOP were 11.1%, 11.8%, and 9.5%, respectively, with lower probabilities observed among patients without on-treatment relapses (8.1%, 8.4%, and 5.7%, respectively). Conclusions In TOP patients with a median (range) baseline EDSS score of 3.5 (0.0–9.5) who completed 24 months of natalizumab treatment, the rate of 48-week confirmed disability worsening events was below 15%; after approximately 5.5 years of natalizumab treatment, 86.5% and 94.7% of patients did not have EDSS score increases of ≥1.0 or ≥2.0 points, respectively. The presence of relapses was associated with higher rates of overall disability worsening. These results were confirmed by assessing transition to EDSS milestones. Lower rates of overall 48-week confirmed EDSS worsening and of transitioning from EDSS score 4.0–5.0 to ≥6.0 in the absence of relapses suggest that relapses remain a significant driver of disability worsening and that on-treatment relapses in natalizumab-treated patients are of prognostic importance

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.

BACKGROUND: A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. METHODS: This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. FINDINGS: Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0-75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4-97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8-80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3-4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. INTERPRETATION: ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials. FUNDING: UK Research and Innovation, National Institutes for Health Research (NIHR), Coalition for Epidemic Preparedness Innovations, Bill & Melinda Gates Foundation, Lemann Foundation, Rede D'Or, Brava and Telles Foundation, NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland's NIHR Clinical Research Network, and AstraZeneca

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Background A safe and efficacious vaccine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), if deployed with high coverage, could contribute to the control of the COVID-19 pandemic. We evaluated the safety and efficacy of the ChAdOx1 nCoV-19 vaccine in a pooled interim analysis of four trials. Methods This analysis includes data from four ongoing blinded, randomised, controlled trials done across the UK, Brazil, and South Africa. Participants aged 18 years and older were randomly assigned (1:1) to ChAdOx1 nCoV-19 vaccine or control (meningococcal group A, C, W, and Y conjugate vaccine or saline). Participants in the ChAdOx1 nCoV-19 group received two doses containing 5 × 1010 viral particles (standard dose; SD/SD cohort); a subset in the UK trial received a half dose as their first dose (low dose) and a standard dose as their second dose (LD/SD cohort). The primary efficacy analysis included symptomatic COVID-19 in seronegative participants with a nucleic acid amplification test-positive swab more than 14 days after a second dose of vaccine. Participants were analysed according to treatment received, with data cutoff on Nov 4, 2020. Vaccine efficacy was calculated as 1 - relative risk derived from a robust Poisson regression model adjusted for age. Studies are registered at ISRCTN89951424 and ClinicalTrials.gov, NCT04324606, NCT04400838, and NCT04444674. Findings Between April 23 and Nov 4, 2020, 23 848 participants were enrolled and 11 636 participants (7548 in the UK, 4088 in Brazil) were included in the interim primary efficacy analysis. In participants who received two standard doses, vaccine efficacy was 62·1% (95% CI 41·0–75·7; 27 [0·6%] of 4440 in the ChAdOx1 nCoV-19 group vs71 [1·6%] of 4455 in the control group) and in participants who received a low dose followed by a standard dose, efficacy was 90·0% (67·4–97·0; three [0·2%] of 1367 vs 30 [2·2%] of 1374; pinteraction=0·010). Overall vaccine efficacy across both groups was 70·4% (95·8% CI 54·8–80·6; 30 [0·5%] of 5807 vs 101 [1·7%] of 5829). From 21 days after the first dose, there were ten cases hospitalised for COVID-19, all in the control arm; two were classified as severe COVID-19, including one death. There were 74 341 person-months of safety follow-up (median 3·4 months, IQR 1·3–4·8): 175 severe adverse events occurred in 168 participants, 84 events in the ChAdOx1 nCoV-19 group and 91 in the control group. Three events were classified as possibly related to a vaccine: one in the ChAdOx1 nCoV-19 group, one in the control group, and one in a participant who remains masked to group allocation. Interpretation ChAdOx1 nCoV-19 has an acceptable safety profile and has been found to be efficacious against symptomatic COVID-19 in this interim analysis of ongoing clinical trials